

May 20, 2013

To whom it may concern

NanoCarrier Co., Ltd.  
Ichiro Nakatomi, Ph.D., President & CEO  
(Code No.: 4571 Tokyo Stock Exchange Mothers)

**Signing of Non-exclusive Sales License Agreement for Nucleotide Delivery Polymer  
with NOF Corporation Ltd.**

As previously announced on December 21, 2009, NanoCarrier granted to NOF Corporation (Headquarter: Shibuya-ku, Tokyo, President & CEO: Mr. Akiharu Kobayashi, hereinafter referred to as “NOF”), the exclusive license limited to “Gene Therapy” market with sub-licensing right using functional protein expressed gene. Tokyo, Japan, May 20, 2013, we are pleased to announce that NanoCarrier signed a non-exclusive, world-wide sales license agreement with NOF other than the gene therapies for the reagent sales of NanoCarrier’s patented polymer.

This technology, developed by our scientific advisor of Professor Kazunori Kataoka of the University of Tokyo and his group, is the micellar nanoparticle technology encapsulated into polymer-ion complex with anionic charged nucleotide such as siRNA using cationic poly-amino acid derivatives as PEG-P[Asp(DET)].

NOF will manufacture and sell the research reagents using this technology to the third party for the research purposes mainly for nucleotide pharmaceutical development such as siRNA therapeutics. NanoCarrier expects to receive the royalty according to the sales from NOF.

NanoCarrier has been challenging not only this technology but also the other technology developments and owns several nucleic acid delivery systems in order to succeed the drug development of appropriate nucleotide pharmaceutical products by selecting an applicable system against the target materials.

The effect is already included in the financial projections for the FY2013, which ends in March 2014.

About NOF Corporation Ltd.

Having “The NOF Group is dedicated to contributing to mankind and society through the creation of new value from the biosphere to outer space” as its management philosophy, NOF is engaging in multifaceted business developments with unique and differentiated products. Especially in the Drug Delivery System (DDS) business, NOF is focusing on the development and sales of source materials and prescription for the application of drug delivery system.

URL: <http://www.nof.co.jp>

Contact: Takuma Nakatsuka,  
CFO and Director of Administration, Head of President’s Office  
TEL. +81-3-3548-0217  
Info@nanocarrier.co.jp